SELECXINE

Selecxine is a biopharmaceutical development company specialized in the field of immunotherapeutics. Selecxine strives to develop immunotherapeutics – a new paradigm of pharmaceuticals– through a specialized antibody development process, using an innovative platform technology of functional antibody screening and development. We endeavor to improve the survival rate and quality of life of cancer patients by developing anti-cancer immunotherapeutics that selectively stimulate the immune cells. These agents act against tumor cells through the regulation of cytokine function, which plays a key role in the enter cell activities. Based on our technology and expertise in the pharmacology and development field, we aim to provide safe and efficient therapeutics and innovative solutions for next-generation pharmaceuticals. CEO, Selecxine Inc. Jun-Young Lee